查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1371921

2030 年生物製藥市場預測：按產品類型、應用和地區分類的全球分析

Biopharmaceuticals Market Forecasts to 2030 - Global Analysis By Product Type, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球生物製藥市場規模為 10.4745 億美元，預計預測期內年複合成長率為 14.4%，到 2030 年將達到 26.8605 億美元。

生物製藥，也稱為生物製藥或生技藥品，是由細胞、有機體和蛋白質等活生物體製成的藥物。這些藥物是利用生物技術製造的，對現代醫療保健至關重要。此外，生物製藥也促進了個人化醫療策略的發展。這些藥物有可能針對患者疾病的特定方面，從而可以根據患者的特定遺傳特徵或疾病亞型製定個體化治療計劃。

根據國際癌症研究機構的數據，2020年約有1,930萬人新診斷出癌症，約1,000萬人死亡。從 2020 年到 2040 年，癌症患者數量預計將增加 47%。

擴大科學進步

結構生物學、基因編輯和高通量篩選方法等不斷發展的科學進步正在改變生物製藥的研究和開發。冷凍電子顯微鏡和尖端成像技術提供的雙分子結構的理解有助於藥物設計。使用人工智慧和機器學習分析大量資料，以對藥物研發做出預測。此外，CRISPR-Cas9 等合成生物學的進步正在使基因治療和基因編輯細胞療法成為可能，從而擴大了生物製藥的範圍。

開發成本過高

生物製藥的發展需要在研究、臨床前測試和具有挑戰性的臨床試驗方面進行財務投資。除了這些基本成本之外，生物製藥公司還必須花費在專門的基礎設施上，例如最先進的實驗室設備和專門的生產設施，所有這些都會增加開發成本。此外，生物製藥開發的長期性和資源集中，單一候選藥物的成本往往超過數十億美元，進一步加劇了財務挑戰。

臨床試驗和個人化醫療的增加

基因組科學和分子診斷的進步使精準醫學成為可能，根據患者的遺傳特徵和特定疾病特徵量身定做治療方法。此策略提高了治療效果，最大限度地減少副作用並最佳化患者的治療效果。此外，腫瘤學是個人化醫療特別有前途的領域，因為生物標記主導的治療正在提高存活率和緩解率。

智慧財產權 (IP) 挑戰

生物製藥市場的全球性創造了一個複雜的專利、商業機密和專利網路，帶來了新的智慧財產權挑戰。此外，生物相似藥的出現帶來了新的法律複雜性，例如專利糾紛和專利叢林策略，這些策略使用多個專利來涵蓋單一產品並提供擴展的市場獨佔權。

COVID-19 的影響：

COVID-19大流行在許多方面對生物製藥行業產生了重大影響。對疫苗和治療方法的迫切需求加速了研發工作，同時也導致了臨床試驗的延誤、全球供應鏈的中斷以及資源重新集中到與疫情相關的活動上。此外，疫情凸顯了疫苗開發、抗病毒療法和生物製藥創新的重要性，導致這些領域的投資增加。它也暴露了供應鏈的弱點，迫使公司重新考慮分銷和製造計劃。

預計疫苗領域在預測期內將是最大的產業。

疫苗領域通常佔據最大的市場。疫苗可預防多種感染疾病，對公共衛生至關重要。對於當前的威脅（如 COVID-19）和新的威脅（如流感和肝炎），疫苗變得越來越受歡迎。全球對疫苗的需求急劇增加，特別是由於 COVID-19 大流行。然而，由於持續的研發活動，包括創建 mRNA 疫苗等新疫苗平台，疫苗市場對於生物製藥行業的擴張和改善公眾健康的配合措施仍然至關重要。

預計癌症領域在預測期內年複合成長率最高

生物製藥市場年複合成長率最高的預計將出現在腫瘤領域。其主要原因包括全球癌症罹患率上升、標靶治療和免疫療法的進步以及精準醫療技術的持續研究。此外，由於針對各種癌症類型的新型生物藥品的開發以及聯合治療和生物標記主導治療的潛力，腫瘤學市場正在經歷顯著成長。

比例最高的地區：

全球生物製藥市場通常佔據北美地區，尤其是美國的最大佔有率。造成這一優勢的因素包括強大的製藥業、大量的研發支出、發達的醫療保健系統、龐大的患者基礎以及支持生物製藥開發和商業化的法規環境。此外，北美擁有大量生物製藥公司、學術研究中心和生物技術中心，這也有助於提高其市場佔有率。

複合年複合成長率最高的地區：

生物製藥市場年複合成長率最高的是亞太地區。中等收入人口的成長、醫療保健成本的上升、藥品製造能力的提高以及對最先進治療的需求不斷增加只是該行業蓬勃發展的部分原因。對生物製藥和疫苗的研發、臨床試驗以及製造的投資尤其使中國和印度等國家成為生物製藥產業的主要企業。此外，該地區的快速成長也得到了政府的支持政策以及與大型製藥企業的合作夥伴關係的支持。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球生物製藥市場：依產品類型

  • 單株抗體
    • 抗癌單株抗體
    • 發炎單株抗體
  • 干擾素
  • 胰島素
  • 生長因子和凝血因子
  • 疫苗
    • 重組疫苗
      • 癌症疫苗
      • 瘧疾疫苗
      • 伊波拉疫苗
      • 乙型肝炎疫苗
      • 破傷風疫苗
      • 白喉疫苗
      • 霍亂疫苗
    • 常規疫苗
      • 小兒麻痺疫苗
      • 痘疫苗
  • 重組生長因子
    • 促紅血球生成素
    • 顆粒細胞增生因子
  • 精製蛋白
    • 白血病抑制因子（LIF）
    • P53蛋白
    • P38蛋白
  • 重組蛋白
    • 血清白蛋白
    • 澱粉樣蛋白
    • 防禦素
    • 轉鐵蛋白
  • 合成免疫調節劑
  • 重組激素
    • 重組人生長激素
    • 重組胰島素
  • 重組酵素
    • 腸激酶
    • 環化酶
    • 胱天蛋白酶
    • 組織蛋白酶
  • 細胞和基因治療
    • 同種異體產品
    • 自我產品
    • 無細胞產品
  • 合成免疫調節劑
    • 細胞因子
    • 干擾素
    • 白血球介素
  • 其他產品類型

第6章 全球生物製藥市場：依應用分類

  • 腫瘤學
  • 血液疾病
  • 代謝性疾病
  • 感染疾病
  • 循環系統疾病
  • 神經系統疾病
  • 免疫學
  • 自體免疫疾病
  • 荷爾蒙失調
  • 其他用途

第7章 全球生物製藥市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第8章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第9章 公司簡介

  • Merck & Co., Inc.
  • Novartis AG
  • Abbott Laboratories.
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Biogen Inc.
  • AbbVie Inc.
  • Pfizer Inc.
  • Bausch Health Companies Inc.
  • F. Hoffmann-La Roche AG
  • Sanofi
  • Bayer AG
  • Allergan plc
  • Johnson & Johnson
  • Amgen Inc.
Product Code: SMRC23978

According to Stratistics MRC, the Global Biopharmaceuticals Market is accounted for $1047.45 million in 2023 and is expected to reach $2686.05 million by 2030 growing at a CAGR of 14.4% during the forecast period. Biopharmaceuticals, also referred to as biologic drugs or biologics, are pharmaceuticals made from living things like cells, organisms, or proteins. These medications are produced using biotechnology techniques and are essential to contemporary healthcare. Moreover, biopharmaceuticals have made it possible to develop personalized medicine strategies. These medications have the potential to target particular molecular aspects of a patient's illness, enabling the development of personalized treatment plans based on the patient's particular genetic profile or disease subtype.

According to the International Agency for Research on Cancer, in the year 2020, around 19.3 million new cases of cancer were diagnosed and around 10 million cancer deaths were recorded. The cancer cases are estimated to grow by 47% from 2020 to 2040.

Market Dynamics:

Driver:

Expanding scientific advances

Biopharmaceutical R&D is being transformed by ongoing scientific advances in structural biology, gene editing, and high-throughput screening methods. Drug design is aided by the understanding of bimolecular structures provided by cryo-electron microscopy and cutting-edge imaging technologies. Massive datasets are analyzed using artificial intelligence and machine learning to make predictions about drug discovery. Additionally, gene therapies and gene-edited cell therapies have been made possible by advances in synthetic biology, such as CRISPR-Cas9, expanding the range of biopharmaceuticals.

Restraint:

Excess development costs

Financial investments in research, preclinical studies, and challenging clinical trials are significant in the development of biopharmaceuticals. In addition to these basic costs, biopharmaceutical businesses also have to spend money on specialized infrastructure, such as state-of-the-art lab tools and specialized manufacturing facilities, all of which drive up development costs. Furthermore, the lengthy and resource-intensive nature of biopharmaceutical development, where costs frequently exceed billions of dollars for a single drug candidate, further exacerbates financial difficulties.

Opportunity:

Increasing clinical trials and personalized medicine

Precision medicine, which tailors treatments to a person's genetic profile and particular disease characteristics, is being made possible by developments in genomics and molecular diagnostics. With this strategy, treatment effectiveness is improved, side effects are minimized, and patient outcomes are optimized. Moreover, oncology is a field where personalized medicine holds particular promise because biomarker-driven therapies are increasing survival and response rates.

Threat:

Challenges to intellectual property (IP)

A complex web of patents, trade secrets, and patent thickets must be negotiated by businesses due to the global nature of the biopharmaceutical market, which presents additional IP challenges. Additionally, the emergence of biosimilars brings with it new legal complexities, such as patent disputes and patent thicket strategies, where multiple patents are used to cover a single product and provide for extended market exclusivity.

COVID-19 Impact:

The COVID-19 pandemic affected the biopharmaceutical industry significantly and in a variety of ways. In addition to delaying clinical trials, disrupting global supply chains, and refocusing resources on pandemic-related activities, the urgent need for vaccines and treatments accelerated research and development efforts. Moreover, the pandemic highlighted the significance of vaccine development, antiviral therapies, and biopharmaceutical innovation, leading to increased investments in these fields. It also exposed weaknesses in supply chains, forcing businesses to reconsider their distribution and manufacturing plans.

The Vaccines segment is expected to be the largest during the forecast period

The vaccines segment typically holds the largest share of the market. A wide range of infectious diseases are prevented by vaccines, which are essential to public health. They have become more well-known for both current threats like COVID-19 and emerging ones like influenza and hepatitis. The global demand for vaccines has increased dramatically as a result of the COVID-19 pandemic in particular. However, the vaccine market is still essential to the expansion of the biopharmaceutical industry and efforts to improve public health due to ongoing research and development activities, including the creation of new vaccine platforms like mRNA vaccines.

The Oncology segment is expected to have the highest CAGR during the forecast period

The biopharmaceutical market's highest CAGR is anticipated in the oncology segment. This is mainly because of a number of things, such as the rising incidence of cancer globally, developments in targeted and immunotherapeutic therapies, and ongoing work on precision medicine methods. Moreover, the oncology market has experienced significant growth as a result of the creation of novel biopharmaceuticals for various cancer types as well as the potential for combination therapies and biomarker-driven treatments.

Region with largest share:

The global biopharmaceutical market typically holds the largest share in the North American region, in particular the United States. A strong pharmaceutical industry, significant R&D expenditures, a developed healthcare system, a sizable patient base, and a supportive regulatory environment for the development and commercialization of biopharmaceuticals were all cited as contributing factors to this dominance. Additionally, its sizeable market share was influenced by the fact that North America is home to a large number of biopharmaceutical businesses, academic research centers, and biotechnology hubs.

Region with highest CAGR:

The biopharmaceutical market was growing at the highest CAGR in the Asia-Pacific region. A rising middle-class population, rising healthcare costs, growing pharmaceutical manufacturing capacity, and rising demand for cutting-edge treatments are just a few of the reasons for this industry's rapid growth. Due to their investments in R&D, clinical trials, and the production of biologic drugs and vaccines, nations like China and India in particular were emerging as major players in the biopharmaceutical industry. Moreover, the region's rapid growth was also aided by supportive government policies and partnerships with major pharmaceutical corporations.

Key players in the market:

Some of the key players in Biopharmaceuticals market include: Merck & Co., Inc. , Novartis AG, Abbott Laboratories., Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca PLC, Bristol-Myers Squibb Company, Biogen Inc. , AbbVie Inc., Pfizer Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche AG, Sanofi, Bayer AG, Allergan plc , Johnson & Johnson and Amgen Inc.

Key Developments:

In October 2023, Sanofi has reached an agreement to develop and commercialize an experimental vaccine candidate for extra intestinal pathogenic E. coli developed by Janssen Pharmaceuticals. Under the terms of the deal, Sanofi will pay the Johnson & Johnson unit $175m upfront, followed by development and commercial milestones. Both parties will co-fund current and future research and development costs. Extra intestinal pathogenic E. coli is a common gram-negative bacteria pathogen in humans and a leading cause of sepsis, particularly in older adults.

In October 2023, Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform. The company's Library of Libraries, a collection of synthetic antibody libraries that harnesses innovative structural and develops ability features to cover a wide range of antibody drug targets, is tailored to address specific challenges in antibody discovery. It has the potential to increase the probability of success of antibody discovery programs across indications and focus areas.

In September 2023, Abbott signs definitive agreement to acquire Bigfoot Biomedical. Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

Product Types Covered:

  • Monoclonal Antibodies
  • Interferon
  • Insulin
  • Growth and Coagulation Factor
  • Vaccines
  • Recombinant Growth Factors
  • Purified Proteins
  • Recombinant Proteins
  • Synthetic Immunomodulators
  • Recombinant Hormones
  • Recombinant Enzymes
  • Cell and Gene Therapies
  • Synthetic Immunomodulators
  • Other Product Types

Applications Covered:

  • Oncology
  • Blood disorder
  • Metabolic disease
  • Infectious disease
  • Cardiovascular disease
  • Neurological disease
  • Immunology
  • Autoimmune Disorders
  • Hormonal Disorders
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Biopharmaceuticals Market, By Product Type

  • 5.1 Introduction
  • 5.2 Monoclonal Antibodies
    • 5.2.1 Anti-cancer Monoclonal Antibodies
    • 5.2.2 Anti-inflammatory Monoclonal Antibodies
  • 5.3 Interferon
  • 5.4 Insulin
  • 5.5 Growth and Coagulation Factor
  • 5.6 Vaccines
    • 5.6.1 Recombinant Vaccines
      • 5.6.1.1 Cancer Vaccine
      • 5.6.1.2 Malaria Vaccine
      • 5.6.1.3 Ebola Vaccine
      • 5.6.1.4 Hepatitis-B Vaccine
      • 5.6.1.5 Tetanus Vaccine
      • 5.6.1.6 Diphtheria Vaccine
      • 5.6.1.7 Cholera Vaccine
    • 5.6.2 Conventional Vaccines
      • 5.6.2.1 Polio Vaccine
      • 5.6.2.2 Pox Vaccine
  • 5.7 Recombinant Growth Factors
    • 5.7.1 Erythropoietin
    • 5.7.2 Granulocyte Colony Stimulating Factor
  • 5.8 Purified Proteins
    • 5.8.1 Leukemia Inhibitory Factor (LIF)
    • 5.8.2 P53 Protein
    • 5.8.3 P38 Protein
  • 5.9 Recombinant Proteins
    • 5.9.1 Serum Albumin
    • 5.9.2 Amyloid Protein
    • 5.9.3 Defensin
    • 5.9.4 Transferrin
  • 5.10 Synthetic Immunomodulators
  • 5.11 Recombinant Hormones
    • 5.11.1 Recombinant Human Growth Hormones
    • 5.11.2 Recombinant Insulin
  • 5.12 Recombinant Enzymes
    • 5.12.1 Enterokinase
    • 5.12.2 Cyclase
    • 5.12.3 Caspase
    • 5.12.4 Cathepsin
  • 5.13 Cell and Gene Therapies
    • 5.13.1 Allogenic Products
    • 5.13.2 Autologous Products
    • 5.13.3 Acellular Products
  • 5.14 Synthetic Immunomodulators
    • 5.14.1 Cytokines
    • 5.14.2 Interferons
    • 5.14.3 Interleukins
  • 5.15 Other Product Types

6 Global Biopharmaceuticals Market, By Application

  • 6.1 Introduction
  • 6.2 Oncology
  • 6.3 Blood disorder
  • 6.4 Metabolic disease
  • 6.5 Infectious disease
  • 6.6 Cardiovascular disease
  • 6.7 Neurological disease
  • 6.8 Immunology
  • 6.9 Autoimmune Disorders
  • 6.10 Hormonal Disorders
  • 6.11 Other Applications

7 Global Biopharmaceuticals Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Merck & Co., Inc.
  • 9.2 Novartis AG
  • 9.3 Abbott Laboratories.
  • 9.4 Novo Nordisk A/S
  • 9.5 Eli Lilly and Company
  • 9.6 AstraZeneca PLC
  • 9.7 Bristol-Myers Squibb Company
  • 9.8 Biogen Inc.
  • 9.9 AbbVie Inc.
  • 9.10 Pfizer Inc.
  • 9.11 Bausch Health Companies Inc.
  • 9.12 F. Hoffmann-La Roche AG
  • 9.13 Sanofi
  • 9.14 Bayer AG
  • 9.15 Allergan plc
  • 9.16 Johnson & Johnson
  • 9.17 Amgen Inc.

List of Tables

  • Table 1 Global Biopharmaceuticals Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Biopharmaceuticals Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Biopharmaceuticals Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 4 Global Biopharmaceuticals Market Outlook, By Anti-cancer Monoclonal Antibodies (2021-2030) ($MN)
  • Table 5 Global Biopharmaceuticals Market Outlook, By Anti-inflammatory Monoclonal Antibodies (2021-2030) ($MN)
  • Table 6 Global Biopharmaceuticals Market Outlook, By Interferon (2021-2030) ($MN)
  • Table 7 Global Biopharmaceuticals Market Outlook, By Insulin (2021-2030) ($MN)
  • Table 8 Global Biopharmaceuticals Market Outlook, By Growth and Coagulation Factor (2021-2030) ($MN)
  • Table 9 Global Biopharmaceuticals Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 10 Global Biopharmaceuticals Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 11 Global Biopharmaceuticals Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
  • Table 12 Global Biopharmaceuticals Market Outlook, By Recombinant Growth Factors (2021-2030) ($MN)
  • Table 13 Global Biopharmaceuticals Market Outlook, By Erythropoietin (2021-2030) ($MN)
  • Table 14 Global Biopharmaceuticals Market Outlook, By Granulocyte Colony Stimulating Factor (2021-2030) ($MN)
  • Table 15 Global Biopharmaceuticals Market Outlook, By Purified Proteins (2021-2030) ($MN)
  • Table 16 Global Biopharmaceuticals Market Outlook, By Leukemia Inhibitory Factor (LIF) (2021-2030) ($MN)
  • Table 17 Global Biopharmaceuticals Market Outlook, By P53 Protein (2021-2030) ($MN)
  • Table 18 Global Biopharmaceuticals Market Outlook, By P38 Protein (2021-2030) ($MN)
  • Table 19 Global Biopharmaceuticals Market Outlook, By Recombinant Proteins (2021-2030) ($MN)
  • Table 20 Global Biopharmaceuticals Market Outlook, By Serum Albumin (2021-2030) ($MN)
  • Table 21 Global Biopharmaceuticals Market Outlook, By Amyloid Protein (2021-2030) ($MN)
  • Table 22 Global Biopharmaceuticals Market Outlook, By Defensin (2021-2030) ($MN)
  • Table 23 Global Biopharmaceuticals Market Outlook, By Transferrin (2021-2030) ($MN)
  • Table 24 Global Biopharmaceuticals Market Outlook, By Synthetic Immunomodulators (2021-2030) ($MN)
  • Table 25 Global Biopharmaceuticals Market Outlook, By Recombinant Hormones (2021-2030) ($MN)
  • Table 26 Global Biopharmaceuticals Market Outlook, By Recombinant Human Growth Hormones (2021-2030) ($MN)
  • Table 27 Global Biopharmaceuticals Market Outlook, By Recombinant Insulin (2021-2030) ($MN)
  • Table 28 Global Biopharmaceuticals Market Outlook, By Recombinant Enzymes (2021-2030) ($MN)
  • Table 29 Global Biopharmaceuticals Market Outlook, By Enterokinase (2021-2030) ($MN)
  • Table 30 Global Biopharmaceuticals Market Outlook, By Cyclase (2021-2030) ($MN)
  • Table 31 Global Biopharmaceuticals Market Outlook, By Caspase (2021-2030) ($MN)
  • Table 32 Global Biopharmaceuticals Market Outlook, By Cathepsin (2021-2030) ($MN)
  • Table 33 Global Biopharmaceuticals Market Outlook, By Cell and Gene Therapies (2021-2030) ($MN)
  • Table 34 Global Biopharmaceuticals Market Outlook, By Allogenic Products (2021-2030) ($MN)
  • Table 35 Global Biopharmaceuticals Market Outlook, By Autologous Products (2021-2030) ($MN)
  • Table 36 Global Biopharmaceuticals Market Outlook, By Acellular Products (2021-2030) ($MN)
  • Table 37 Global Biopharmaceuticals Market Outlook, By Synthetic Immunomodulators (2021-2030) ($MN)
  • Table 38 Global Biopharmaceuticals Market Outlook, By Cytokines (2021-2030) ($MN)
  • Table 39 Global Biopharmaceuticals Market Outlook, By Interferons (2021-2030) ($MN)
  • Table 40 Global Biopharmaceuticals Market Outlook, By Interleukins (2021-2030) ($MN)
  • Table 41 Global Biopharmaceuticals Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 42 Global Biopharmaceuticals Market Outlook, By Application (2021-2030) ($MN)
  • Table 43 Global Biopharmaceuticals Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 44 Global Biopharmaceuticals Market Outlook, By Blood disorder (2021-2030) ($MN)
  • Table 45 Global Biopharmaceuticals Market Outlook, By Metabolic disease (2021-2030) ($MN)
  • Table 46 Global Biopharmaceuticals Market Outlook, By Infectious disease (2021-2030) ($MN)
  • Table 47 Global Biopharmaceuticals Market Outlook, By Cardiovascular disease (2021-2030) ($MN)
  • Table 48 Global Biopharmaceuticals Market Outlook, By Neurological disease (2021-2030) ($MN)
  • Table 49 Global Biopharmaceuticals Market Outlook, By Immunology (2021-2030) ($MN)
  • Table 50 Global Biopharmaceuticals Market Outlook, By Autoimmune Disorders (2021-2030) ($MN)
  • Table 51 Global Biopharmaceuticals Market Outlook, By Hormonal Disorders (2021-2030) ($MN)
  • Table 52 Global Biopharmaceuticals Market Outlook, By Other Applications (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.